AzurRx BioPharma, Inc.
Company Snapshot: AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections.
- Jan 18 2018 AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency
- Jan 16 2018 AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants
- Dec 20 2017 AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101
- Dec 4 2017 AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)